EyePoint (EYPT) stock crashed on Oct. 19 as another pivotal trial disappointment prompted the biotech firm to announce sweeping job cuts. EYPT’s experimental eye treatment, DURAVYU, missed its primary endpoint in the Phase 3 study for wet age-related macular degeneration.
Management responded with plans to eliminate roughly 53% of its workforce and redirect resources toward diabetic macular edema.
